Alirocumab OverviewAlirocumab (trade name Praluent) is a biopharmaceutical drug approved by the FDA on July 24, 2015 as a second line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal antibody that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials...
Read more Alirocumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Alirocumab
Recent Alirocumab Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 150mg, 75mg
Other drugs which contain Alirocumab or a similar ingredient: (1 result)
- PRALUENT Alirocumab